These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 28286210)

  • 41. Evaluating the efficacy of 8 non-invasive models in predicting MASLD and progression: a prospective study.
    Yang A; Zhu X; Zhang L; Zhang D; Jin M; Lv G; Ding Y
    BMC Gastroenterol; 2024 Oct; 24(1):365. PubMed ID: 39402469
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis.
    Gu J; Liu S; Du S; Zhang Q; Xiao J; Dong Q; Xin Y
    Eur Radiol; 2019 Jul; 29(7):3564-3573. PubMed ID: 30899974
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial.
    Le TA; Chen J; Changchien C; Peterson MR; Kono Y; Patton H; Cohen BL; Brenner D; Sirlin C; Loomba R;
    Hepatology; 2012 Sep; 56(3):922-32. PubMed ID: 22431131
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Accuracy of common proton density fat fraction thresholds for magnitude- and complex-based chemical shift-encoded MRI for assessing hepatic steatosis in patients with obesity.
    Cunha GM; Thai TT; Hamilton G; Covarrubias Y; Schlein A; Middleton MS; Wiens CN; McMillan A; Agni R; Funk LM; Campos GM; Horgan S; Jacobson G; Wolfson T; Gamst A; Schwimmer JB; Reeder SB; Sirlin CB
    Abdom Radiol (NY); 2020 Mar; 45(3):661-671. PubMed ID: 31781899
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD.
    Permutt Z; Le TA; Peterson MR; Seki E; Brenner DA; Sirlin C; Loomba R
    Aliment Pharmacol Ther; 2012 Jul; 36(1):22-9. PubMed ID: 22554256
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Marked difference in liver fat measured by histology
    Qadri S; Vartiainen E; Lahelma M; Porthan K; Tang A; Idilman IS; Runge JH; Juuti A; Penttilä AK; Dabek J; Lehtimäki TE; Seppänen W; Arola J; Arkkila P; Stoker J; Karcaaltincaba M; Pavlides M; Loomba R; Sirlin CB; Tukiainen T; Yki-Järvinen H
    JHEP Rep; 2024 Jan; 6(1):100928. PubMed ID: 38089550
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Proton density fat-fraction is an accurate biomarker of hepatic steatosis in adolescent girls and young women.
    Rehm JL; Wolfgram PM; Hernando D; Eickhoff JC; Allen DB; Reeder SB
    Eur Radiol; 2015 Oct; 25(10):2921-30. PubMed ID: 25916386
    [TBL] [Abstract][Full Text] [Related]  

  • 48. MR quantitative biomarkers of non-alcoholic fatty liver disease: technical evolutions and future trends.
    Ligabue G; Besutti G; Scaglioni R; Stentarelli C; Guaraldi G
    Quant Imaging Med Surg; 2013 Aug; 3(4):192-5. PubMed ID: 24040614
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Assessing hepatic steatosis by magnetic resonance in potential living liver donors.
    Kuru Öz D; Ellik Z; Gürsoy Çoruh A; Adıgüzel M; Gümüşsoy M; Kiremitci S; Kırımker OE; Gökcan H; Elhan AH; Balcı D; Savaş B; Erden A; İdilman R
    Diagn Interv Radiol; 2024 Nov; 30(6):351-356. PubMed ID: 38737404
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis.
    Tang A; Tan J; Sun M; Hamilton G; Bydder M; Wolfson T; Gamst AC; Middleton M; Brunt EM; Loomba R; Lavine JE; Schwimmer JB; Sirlin CB
    Radiology; 2013 May; 267(2):422-31. PubMed ID: 23382291
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Radiomics Analysis of Magnetic Resonance Proton Density Fat Fraction for the Diagnosis of Hepatic Steatosis in Patients With Suspected Non-Alcoholic Fatty Liver Disease.
    Sim KC; Kim MJ; Cho Y; Kim HJ; Park BJ; Sung DJ; Han NY; Han YE; Kim TH; Lee YJ
    J Korean Med Sci; 2022 Dec; 37(49):e339. PubMed ID: 36536543
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vivo breath-hold (1) H MRS simultaneous estimation of liver proton density fat fraction, and T1 and T2 of water and fat, with a multi-TR, multi-TE sequence.
    Hamilton G; Middleton MS; Hooker JC; Haufe WM; Forbang NI; Allison MA; Loomba R; Sirlin CB
    J Magn Reson Imaging; 2015 Dec; 42(6):1538-43. PubMed ID: 26114603
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A pilot study of ex-vivo MRI-PDFF of donor livers for assessment of steatosis and predicting early graft dysfunction.
    Satapathy SK; Gonzalez HC; Vanatta J; Dyer A; Angel W; Nouer SS; Kocak M; Kedia SK; Jiang Y; Clark I; Yadak N; Nezakagtoo N; Helmick R; Horton P; Campos L; Agbim U; Maliakkal B; Maluf D; Nair S; Halford HH; Eason JD
    PLoS One; 2020; 15(5):e0232006. PubMed ID: 32407331
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Quantifying steatosis in the liver and pancreas with MRI in patient with chronic liver disease.
    Vieira J; Amorim J; Martí-Bonmatí L; Alberich-Bayarri Á; França M
    Radiologia (Engl Ed); 2020; 62(3):222-228. PubMed ID: 31932016
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Liver fat deposition and mitochondrial dysfunction in morbid obesity: An approach combining metabolomics with liver imaging and histology.
    Calvo N; Beltrán-Debón R; Rodríguez-Gallego E; Hernández-Aguilera A; Guirro M; Mariné-Casadó R; Millá L; Alegret JM; Sabench F; del Castillo D; Vinaixa M; Rodríguez MÀ; Correig X; García-Álvarez R; Menendez JA; Camps J; Joven J
    World J Gastroenterol; 2015 Jun; 21(24):7529-44. PubMed ID: 26140000
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Three-dimensional analysis of pancreatic fat by fat-water magnetic resonance imaging provides detailed characterization of pancreatic steatosis with improved reproducibility.
    Kato S; Iwasaki A; Kurita Y; Arimoto J; Yamamoto T; Hasegawa S; Sato T; Imajo K; Hosono K; Kobayashi N; Yoneda M; Higurashi T; Kubota K; Utsunomiya D; Nakajima A
    PLoS One; 2019; 14(12):e0224921. PubMed ID: 31790429
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quantification of liver, pancreas, kidney, and vertebral body MRI-PDFF in non-alcoholic fatty liver disease.
    Idilman IS; Tuzun A; Savas B; Elhan AH; Celik A; Idilman R; Karcaaltincaba M
    Abdom Imaging; 2015 Aug; 40(6):1512-9. PubMed ID: 25715922
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Simultaneous quantification of hepatic MRI-PDFF and R2* in a rabbit model with nonalcoholic fatty liver disease.
    Wang X; Zhang X; Ma L; Li S
    Sci China Life Sci; 2018 Sep; 61(9):1107-1114. PubMed ID: 29934919
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of Liver Fibrosis and Fatty Liver on T1rho Measurements: A Prospective Study.
    Xie S; Li Q; Cheng Y; Zhang Y; Zhuo Z; Zhao G; Shen W
    Korean J Radiol; 2017; 18(6):898-905. PubMed ID: 29089822
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Quantitative determination of liver triglyceride levels with 3T ¹H-MR spectroscopy in mice with moderately elevated liver fat content.
    Runge JH; Bakker PJ; Gaemers IC; Verheij J; Hakvoort TB; Ottenhoff R; Stoker J; Nederveen AJ
    Acad Radiol; 2014 Nov; 21(11):1446-54. PubMed ID: 25300722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.